액체 생검 시장 규모, 점유율, 성장 및 세계 산업 분석 : 종류별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of liquid biopsy Market

The global liquid biopsy market was valued at USD 11.66 billion in 2025 and is projected to grow to USD 14.23 billion in 2026, reaching a substantial USD 106.49 billion by 2034. The market is expected to expand at a compound annual growth rate (CAGR) of 28.61% during the forecast period. This rapid growth is primarily driven by the rising prevalence of cancer, increasing demand for non-invasive diagnostic techniques, and advancements in molecular diagnostics.

Liquid biopsy refers to the detection and analysis of circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cells, and biomarkers from biological fluids such as blood, cerebrospinal fluid, and amniotic fluid. These tests provide a minimally invasive alternative to traditional tissue biopsies for cancer diagnosis, prognosis, and therapy selection.

Market Size & Value (As per Report Year)

• 2025 Market Size: USD 11.66 billion
• 2026 Market Size: USD 14.23 billion
• 2034 Forecast Market Size: USD 106.49 billion

Key Growth Drivers

The rising global burden of cancer is a major factor fueling market growth. According to ICMR data, cancer incidence in India increased from 1.39 million in 2020 to 1.46 million in 2022, reflecting a broader global trend. This surge has increased the demand for early screening, disease monitoring, and precision oncology solutions.

In addition, liquid biopsy plays a critical role in non-invasive prenatal testing (NIPT), driven by the increasing prevalence of chromosomal abnormalities such as Down syndrome. Government-supported screening initiatives and growing awareness of early disease detection have further boosted adoption.

Regulatory approvals from agencies such as the U.S. FDA for advanced cancer detection assays, along with continuous clinical research and innovation, are significantly supporting market expansion.

Market Restraints

Despite its advantages, the market faces challenges related to high test costs and reimbursement limitations. In the U.S., liquid biopsy tests can cost over USD 2,000 per test, making them less accessible for routine screening. Additionally, reimbursement restrictions-especially for early-stage cancer screening-limit broader adoption, particularly in developing economies such as India and China.

Segmentation Analysis

By Product:

Kits & reagents dominate the market, accounting for 80.08% share in 2026, due to frequent product launches and approvals for ctDNA and NIPT assays. Instruments are expected to grow at a moderate pace, supported by technological advancements in PCR and NGS platforms.

By Application:

Non-invasive prenatal testing (NIPT) held the largest share at 68.69% in 2026, driven by rising prenatal screening demand. The oncology segment is expected to grow at a higher CAGR, supported by increasing use in cancer diagnosis, therapy monitoring, and recurrence detection.

By End User:

Hospitals dominated the market with a 75.01% share in 2026, owing to high patient footfall and increasing adoption of cancer and prenatal tests. Clinical laboratories are expected to register notable growth due to expanding diagnostic infrastructure.

Regional Insights

North America dominated the global liquid biopsy market with a 54.57% share in 2025, driven by strong R&D investment, early adoption of precision oncology, and favorable reimbursement frameworks.

Europe follows due to government-led cancer screening programs and rising funding for diagnostic innovation.

Asia Pacific is expected to witness the fastest growth, supported by rising cancer prevalence, expanding healthcare access, and growing adoption of NIPT in countries such as China, Japan, and India.

Competitive Landscape

Key players include Guardant Health, Foundation Medicine, Natera, Illumina, Roche, Thermo Fisher Scientific, QIAGEN, and Bio-Rad Laboratories. Companies are focusing on strategic collaborations, clinical trials, and product innovations to strengthen their market presence.

Conclusion

The global liquid biopsy market is poised for strong long-term growth, expanding from USD 11.66 billion in 2025 to USD 106.49 billion by 2034. Rising cancer incidence, increasing preference for non-invasive diagnostics, and advancements in molecular testing technologies are the key growth catalysts. Although high costs and reimbursement challenges remain, continuous innovation, regulatory approvals, and expanding clinical applications are expected to drive widespread adoption, positioning liquid biopsy as a cornerstone of future precision medicine.

Growth Rate CAGR of 28.61% from 2026-2034

Segmentation By Product

• Kits & Reagents
• Instruments

By Application

• Non-invasive Prenatal Testing (NIPT)
• Oncology
• Others

By End User

• Hospitals
• Clinical Laboratories
• Others

By Region

• North America (By Product, By Application, By End User, and By Country)
  • U.S. (By Application)
  • Canada (By Application)
• Europe (By Product, By Application, By End User, and By Country/ Sub-region)
  • Germany (By Application)
  • U.K. (By Application)
  • France (By Application)
  • Italy (By Application)
  • Spain (By Application)
  • Rest of Europe (By Application)
• Asia Pacific (By Product, By Application, By End User, and By Country/ Sub-region)
  • Japan (By Application)
  • China (By Application)
  • India (By Application)
  • Australia (By Application)
  • Southeast Asia (By Application)
  • Rest of Asia Pacific (By Application)
• Latin America (By Product, By Application, By End User, and By Country/ Sub-region)
  • Brazil (By Application)
  • Mexico (By Application)
  • Rest of Latin America (By Application)
• Middle East & Africa (By Product, By Application, By End User, and By Country/ Sub-region)
  • GCC (By Application)
  • South Africa (By Application)
  • Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Cancer, By Key Countries, 2025
• 4.2. Key Industry Developments - Mergers, Partnerships, & Acquisitions
• 4.3. New Product Launches, By Key Players
• 4.4. Impact of COVID-19 on the Market

5. Global Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Kits & Reagents
  • 5.1.2. Instruments
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Non-invasive Prenatal Testing (NIPT)
  • 5.2.2. Oncology
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals
  • 5.3.2. Clinical Laboratories
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East and Africa

6. North America Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Kits & Reagents
  • 6.1.2. Instruments
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Non-invasive Prenatal Testing (NIPT)
  • 6.2.2. Oncology
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals
  • 6.3.2. Clinical Laboratories
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Application
  • 6.4.2. Canada
    • 6.4.2.1. By Application

7. Europe Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Kits & Reagents
  • 7.1.2. Instruments
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Non-invasive Prenatal Testing (NIPT)
  • 7.2.2. Oncology
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals
  • 7.3.2. Clinical Laboratories
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
    • 7.4.1.1. By Application
  • 7.4.2. Germany
    • 7.4.2.1. By Application
  • 7.4.3. France
    • 7.4.3.1. By Application
  • 7.4.4. Spain
    • 7.4.4.1. By Application
  • 7.4.5. Italy
    • 7.4.5.1. By Application
  • 7.4.6. Rest of Europe
    • 7.4.6.1. By Application

8. Asia Pacific Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Kits & Reagents
  • 8.1.2. Instruments
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Non-invasive Prenatal Testing (NIPT)
  • 8.2.2. Oncology
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals
  • 8.3.2. Clinical Laboratories
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
    • 8.4.1.1. By Application
  • 8.4.2. China
    • 8.4.2.1. By Application
  • 8.4.3. India
    • 8.4.3.1. By Application
  • 8.4.4. Australia
    • 8.4.4.1. By Application
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Application
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Application

9. Latin America Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Kits & Reagents
  • 9.1.2. Instruments
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Non-invasive Prenatal Testing (NIPT)
  • 9.2.2. Oncology
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals
  • 9.3.2. Clinical Laboratories
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Application
  • 9.4.2. Mexico
    • 9.4.2.1. By Application
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Application

10. Middle East & Africa Liquid Biopsy Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Kits & Reagents
  • 10.1.2. Instruments
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Non-invasive Prenatal Testing (NIPT)
  • 10.2.2. Oncology
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Hospitals
  • 10.3.2. Clinical Laboratories
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
    • 10.4.1.1. By Application
  • 10.4.2. South Africa
    • 10.4.2.1. By Application
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Application

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Guardant Health
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. PERSONALIS, INC.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. FOUNDATION MEDICINE, INC.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Natera, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Illumina, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. F. Hoffmann-La Roche Ltd
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Menarini Silicon Biosystems, Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Thermo Fisher Scientific Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. QIAGEN
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Bio-Rad Laboratories, Inc.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)